This is an update to the FDA Drug Safety Communication: Anti-seizure drug Potiga (ezogabine) linked to retinal abnormalities and blue skin discoloration issued on 4/26/2013. Safety Announcement [10-31-2013] The U.S. Food and Drug Administration (FDA) has approved changes to the drug label of the anti-seizure drug Potiga (ezogabine), underscoring risks of abnormalities to the retina…
FDA Drug Safety Communication: FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales
This update is in follow-up to the FDA Drug Safety Communication: FDA investigating leukemia drug Iclusig (ponatinib) after increased reports of serious blood clots in arteries and veins issued on October 11, 2013. Safety Announcement [10-31-2013] The U.S. Food and Drug Administration (FDA) has asked the manufacturer of the leukemia chemotherapy drug Iclusig (ponatinib) to…
FDA Drug Safety Communication: FDA investigating leukemia drug Iclusig (ponatinib) after increased reports of serious blood clots in arteries and veins
Safety Announcement [10-11-2013]Â The U.S. Food and Drug Administration (FDA) is investigating an increasing frequency of reports of serious and life-threatening blood clots and severe narrowing of blood vessels (arteries and veins) of patients taking the leukemia chemotherapy drug Iclusig (ponatinib). Â Health care professionals should consider for each patient, whether the benefits of Iclusig…
Comunicado de la FDA sobre la seguridad de los medicamentos: Recuadro con advertencia y nuevas recomendaciones para disminuir el riesgo de reactivación de la hepatitis B con los medicamentos Arzerra (ofatumumab) y Rituxan (rituximab), que combaten el cáncer y suprimen el sistema inmunitario
<!– –> <!– Page Last Updated: 10/01/2013 –> Page Last Updated: 10/01/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Comunicado de la FDA sobre la seguridad de los medicamentos: La FDA advierte del aumento del riesgo de muerte con antibiótico Tygacil intravenoso (tigeciclina) y aprueba nuevo Recuadro con advertencia
Esta actualización se hace a manera de seguimiento al Comunicado de la FDA sobre la seguridad del medicamento: Mayor riesgo de muerte con Tygacil (tigeciclina) en comparación con otros antibióticos usados para el tratamiento de infecciones similares emitido el 1º de septiembre del 2010 (información en inglés). Anuncio de seguridad El 27 de septiembre, 2013,…
FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning
<!– –> <!– Page Last Updated: 09/27/2013 –> Page Last Updated: 09/27/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Comunicado de la FDA sobre la seguridad de los medicamentos: FDA requiere cambio de color de parches analgésicos Duragesic (fentanilo) para mayor seguridad y enfatiza que la exposición accidental a parches usados puede causar la muerte
<!– –> <!– Page Last Updated: 09/25/2013 –> Page Last Updated: 09/25/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab)
<!– –> <!– Page Last Updated: 09/25/2013 –> Page Last Updated: 09/25/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA Drug Safety Communication: FDA requiring color changes to Duragesic (fentanyl) pain patches to aid safety―emphasizing that accidental exposure to used patches can cause death
<!– –> <!– Page Last Updated: 09/23/2013 –> Page Last Updated: 09/23/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA investiga infección cerebral poco común en paciente que tomó Gilenya (fingolimod)
<!– –> <!– Page Last Updated: 09/03/2013 –> Page Last Updated: 09/03/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.